phrykt

Immuneering Corp (IMRX): who owns it and who trades it

As of Nov 16, 2026, IMRX insiders reported 8 purchases worth $360K in the last 12 months. The largest buyer was Thomas J. Schall (Director), with $101K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Immuneering

From the latest filings

Overall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IMRX

112 funds and institutions reported IMRX shares worth $172M at the end of Q2 2026. The largest holder is FMR LLC (Fidelity) with $48.4M.

10 largest owners, by value

FMR LLC (Fidelity)$48.4M
BlackRock, Inc.$21.8M
Sanofi$13.5M
Vanguard Capital Management LLC$11.4M
T. Rowe Price Associates$9.7M
Geode Capital Management, LLC$6.8M
State Street Corp$5M
DCF Advisers, LLC$3.9M
Marshall Wace, LLP$3.7M
Connor, Clark & Lunn Investment Management Ltd.$3M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)9.70M–$48.4M+0%
BlackRock, Inc.4.37M–$21.8M+190%
Sanofi2.71M–$13.5MNo change
Vanguard Capital Management LLC2.29M–$11.4M-0%
T. Rowe Price Associates1.94M–$9.7M+6%
Geode Capital Management, LLC1.37M–$6.8M+115%
State Street Corp1.00M–$5M+273%
DCF Advisers, LLC790,000–$3.9M+458%
Marshall Wace, LLP731,897–$3.7M-63%
Connor, Clark & Lunn Investment Management Ltd.601,255–$3M+50%
Alethea Capital Management, LLC472,935–$2.4M+1962%
Summit Financial, LLC452,264–$2.3M+20%
UBS Group AG448,857–$2.2M+19%
Nuveen, LLC438,362–$2.2MNew
Northern Trust Corp436,992–$2.2M+271%
Levin Capital Strategies, L.P.414,000–$2.1M+4040%
Citadel Advisors LLC386,411–$1.9M-14%
Vanguard Fiduciary Trust Co360,764–$1.8M+12%
Vanguard Portfolio Management LLC359,085–$1.8MNew
Gsa Capital Partners LLP343,303–$1.7M+347%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IMRX insiders reported $360K of open-market purchases and $0 of sales.

Purchases, 12 months
$360K
8 trades, 7 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 16, 2026

Purchases and sales by month

$234K$234KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Andrew GengosCFOPurchase25,000$3.58$89.5KForm 4
Jun 23, 2026Benjamin J. ZeskindCEOPurchase2,400$4.56$10.9KForm 4
Jun 15, 2026Brett Matthew HallCHIEF SCIENTIFIC OFFICERPurchase6,035$4.15$25KForm 4
Jan 16, 2026Harold Eugene BrakewoodChief Business OfficerPurchase5,250$4.76$25KForm 4
Jan 15, 2026Thomas J. SchallDirectorPurchase21,645$4.67$101KForm 4
Jan 15, 2026Brett Matthew HallCHIEF SCIENTIFIC OFFICERPurchase2,298$4.57$10.5KForm 4
Jan 13, 2026Leah R NeufeldCHIEF PEOPLE OFFICERPurchase2,626$4.15$10.9KForm 4
Jan 12, 2026Peter FeinbergDirectorPurchase20,000$4.35$87KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Thomas J. SchallDirector$101K–Jan 15, 2026
Andrew GengosChief Financial Officer$89.5K–Nov 13, 2026
Peter FeinbergDirector$87K–Jan 12, 2026
Brett Matthew HallCHIEF SCIENTIFIC OFFICER$35.5K–Jun 15, 2026
Harold Eugene BrakewoodChief Business Officer$25K–Jan 16, 2026
Benjamin J. ZeskindPRESIDENT AND CEO, Director$10.9K–Jun 23, 2026
Leah R NeufeldCHIEF PEOPLE OFFICER$10.9K–Jan 13, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IMRX short interest

14.60M IMRX shares are sold short. Over the last 12 reports the number of shares short went up 48%.

As of Oct 30, 2026, 14.60M IMRX shares were sold short, down 10.6% from the report before. At the average daily volume of 760,062 shares, buying them all back would take about 19.2 trading days (days to cover).

Shares short

14.60MMay 15Oct 3017.29M

Days to cover

19.2May 15Oct 3030.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202614.60M–-11%760,06219.2
Oct 15, 202616.32M–+5%801,86020.4
Sep 30, 202615.49M–-0%639,76524.2
Sep 15, 202615.55M–+5%756,55120.6
Aug 31, 202614.84M–+3%547,45227.1
Aug 14, 202614.43M–-6%745,01319.4
Jul 31, 202615.40M–+1%755,90320.4
Jul 15, 202615.21M–+1%926,95516.4
Jun 30, 202615.03M–+7%1.97M7.6
Jun 15, 202614.03M–+10%2.27M6.2
May 29, 202612.72M–+29%2.57M5.0
May 15, 20269.89M–+4%663,64314.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Immuneering company events

Immuneering filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026LeadershipThe Board of Directors of Immuneering Corporation appointed Grant C. Bogle, MBA, to serve as a member of the Company's Board as a Class III Director. Filing
  2. Oct 29, 2026ResultsReleased financial results. Filing
  3. Aug 5, 2026ResultsReleased financial results. Filing
  4. Jun 15, 2026LeadershipThe Board of Directors of Immuneering Corporation appointed Andrew Gengos as th e Chief Financial Officer and Treasurer of t he Company, to become effective on the commencement of his employment with the Company, which is expected to be on or before July 16, 2026 (the date Mr. Gengos actually… Filing
  5. Jun 11, 2026VoteReported shareholder vote results. Filing
  6. Jun 1, 2026AnnouncementImmuneering Corporation announced updated data from its ongoing Phase 2a clinical trial evaluating atebimetinib (formerly known as IMM-1-104), a once-daily oral mitogen-activated protein kinase kinase (or "MEK") inhibitor, in combination with modified Gemcitabine/nab-Paclitaxel in first-line… Filing
  7. May 15, 2026ResultsReleased financial results. Filing
  8. Mar 6, 2026ResultsReleased financial results. Filing
  9. Jan 7, 2026AnnouncementImmuneering Corporation announced updated interim data from its ongoing Phase 2a clinical trial evaluating atebimetinib (formerly known as IMM-1-104), a once-daily oral mitogen-activated protein kinase kinase (or MEK) inhibitor, in combination with modified Gemcitabine/nab-Paclitaxel in first-line… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Immuneering financials

Famous investors that hold IMRX

3 of the 50 well-known investors we track reported holding IMRX in their latest 13F filing. The largest position is Ken Fisher's, worth $475K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 2026115,954$475K0.0%+31%
Ken Griffin · Citadel AdvisorsQ3 202689,895$368K0.0%-77%
Israel Englander · Millennium ManagementQ3 202643,712$179K0.0%-87%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Immuneering Corp (IMRX) stock

Who owns the most IMRX stock?

The largest reported owner of Immuneering Corp (IMRX) is FMR LLC (Fidelity). In total, 112 funds and institutions reported holding IMRX at the end of Q2 2026. See the largest owners.

Are IMRX insiders buying or selling?

In the last 12 months, IMRX insiders reported 8 open-market purchases worth $360K and no sales. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in IMRX?

As of Oct 30, 2026, 14.60M IMRX shares were sold short, down 10.6% from the report before. At the average daily volume of 760,062 shares, buying them all back would take about 19.2 trading days (days to cover). See the history.

Which famous investors hold IMRX?

3 of the 50 well-known investors we track reported IMRX in their latest 13F filing, including Ken Fisher, Ken Griffin, Israel Englander. The largest position is worth $475K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.